摘要
采用免疫放射分析法对血清总ＰＳＡ（Ｔ－ＰＳＡ）水平介于４－２０μｇ／Ｌ的１４１例良性前列腺增生（ＢＰＨ）患者、２３例前列腺癌（Ｐｃａ）未治疗患者、１１例前列腺癌已治疗患者进行血清游离ＰＳＡ（Ｆ－ＰＳＡ），Ｆ／Ｔ－ＰＳＡ测定。经统计学处理：ＢＰＨ组与Ｐｃａ未治疗组Ｆ－ＰＳＡ及Ｆ／Ｔ－ＰＳＡ均有显著性差异（Ｐ＜０．０１），对两项指标综合评价结果表明Ｆ／Ｔ－ＰＳＡ的总有效率（８９．９％）明显优于Ｔ－ＰＳＡ（５４．８％），Ｔ－ＰＳＡ与Ｆ／Ｔ－ＰＳＡ的临床特性曲线显示在一定灵敏度条件下，Ｆ／Ｔ－ＰＳＡ以１３．２％为阳性界限值，ＢＰＨ组与Ｐｃａ未治疗组诊断符合率分别为９０．８％及８２．６％。因而，Ｆ／Ｔ－ＰＳＡ测定可有助于ＢＰＨ与前列腺癌的鉴别诊断。
Free and total prostate specific antigen (F-PSA and T-PSA) in serum were measured with immunoradiometritic assay and the F/T-PSA ratio was calculated in 175 patients with T-PSA levels in the range of 4-20 μg/L. Among them 141 patients were benign prostatic hyperplasia (BPH), 23 were untreated prostate cancer (Pca untreated) and 11 were treated prostate cancer (Pca treated). The results showed that difference in F-PSA and F/T-PSA ratio for BPH group and Pca untreated group were statistically significant (P<0.01). The effectiveness of F/T-PSA ratio for Pca (89.9%) was higher than F-PSA (54.8%). The receiver-operating characteristic (ROC) curve showed an improved diagnostic efficacy of F/T-PSA ratio compared with T-PSA for discrimination between BPH and Pca. If mean F/T-PSA ratio value+ 1SE (13.2%) was used in BPH group as discrimination limits of Pca patients, the diagnostic accuracy of BPH group and Pca untreated group were 90.8% and 82.6% respectively. Thereby F/T-PSA ratio may be useful for the differentiation between BPH and prostate cancer.
出处
《核技术》
CAS
CSCD
北大核心
1999年第5期301-304,共4页
Nuclear Techniques
基金
国际原子能机构科研合同资助!(No.9317)课题
关键词
前列腺癌
游离
前列腺特异抗原
血清
临床应用
Benign prostatic hyperplasia, Prostate cancer, Free prostate specific antigen, Total prostate specific antigen, Free to total prostate specific antigen ratio
